Guangzhou LBP Medicine Science & Technology Co Ltd
SSE:688393
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Guangzhou LBP Medicine Science & Technology Co Ltd
Other Current Assets
Guangzhou LBP Medicine Science & Technology Co Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Guangzhou LBP Medicine Science & Technology Co Ltd
SSE:688393
|
Other Current Assets
¥207m
|
CAGR 3-Years
170%
|
CAGR 5-Years
133%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Other Current Assets
¥40.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Other Current Assets
¥304m
|
CAGR 3-Years
39%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Other Current Assets
¥522.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
Other Current Assets
¥971.7m
|
CAGR 3-Years
39%
|
CAGR 5-Years
86%
|
CAGR 10-Years
44%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Other Current Assets
¥1.2B
|
CAGR 3-Years
81%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
Guangzhou LBP Medicine Science & Technology Co Ltd
Glance View
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. The company is headquartered in Guangzhou, Guangdong and currently employs 697 full-time employees. The company went IPO on 2020-08-20. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The firm operates its businesses within the domestic market and to overseas markets.
See Also
What is Guangzhou LBP Medicine Science & Technology Co Ltd's Other Current Assets?
Other Current Assets
207m
CNY
Based on the financial report for Dec 31, 2024, Guangzhou LBP Medicine Science & Technology Co Ltd's Other Current Assets amounts to 207m CNY.
What is Guangzhou LBP Medicine Science & Technology Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
133%
Over the last year, the Other Current Assets growth was 77%. The average annual Other Current Assets growth rates for Guangzhou LBP Medicine Science & Technology Co Ltd have been 170% over the past three years , 133% over the past five years .
